Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing
NCT ID: NCT03019822
Last Updated: 2018-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
28 participants
INTERVENTIONAL
2017-02-01
2018-09-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuronal Correlates of Altered States of Consciousness
NCT02308969
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers
NCT02451072
A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine
NCT03609190
Brain Function and EEG
NCT05003076
Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders
NCT00097175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo, LSD, d-Amphetamine, MDMA
Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase
LSD
100ug per os, single dose
MDMA
125mg per os, single dose
Amphetamine
40.3mg per os, single dose
Placebo
Capsules containing mannitol looking identical to the other drugs
LSD, d-Amphetamine, MDMA, Placebo
Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
LSD
100ug per os, single dose
MDMA
125mg per os, single dose
Amphetamine
40.3mg per os, single dose
Placebo
Capsules containing mannitol looking identical to the other drugs
d-Amphetamine, MDMA, LSD, Placebo
Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
LSD
100ug per os, single dose
MDMA
125mg per os, single dose
Amphetamine
40.3mg per os, single dose
Placebo
Capsules containing mannitol looking identical to the other drugs
MDMA, LSD, Placebo, d-Amphetamine,,
Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
LSD
100ug per os, single dose
MDMA
125mg per os, single dose
Amphetamine
40.3mg per os, single dose
Placebo
Capsules containing mannitol looking identical to the other drugs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LSD
100ug per os, single dose
MDMA
125mg per os, single dose
Amphetamine
40.3mg per os, single dose
Placebo
Capsules containing mannitol looking identical to the other drugs
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sufficient understanding of the German language
3. Subjects understand the procedures and the risks associated with the study.
4. Participants must be willing to adhere to the protocol and sign the consent form.
5. Participants must be willing to refrain from taking illicit psychoactive substances during the study.
6. Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drink after midnight of the evening before the study session, as well as during the study day.
7. Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration.
8. Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests are repeated before each study session. Women and men must agree to use an effective form of birth control (double-barrier method).
9. Body mass index 18-29 kg/m2.
Exclusion Criteria
2. Hypertension (\>140/90 mmHg) or Hypotension (SBP\<85 mmHg)
3. Current or previous major psychiatric disorder
4. Psychotic disorder in first-degree relatives
5. Illicit substance use (with the exception of cannabis) more than 10 times or any time within the previous two months.
6. Pregnant or nursing women.
7. Participation in another clinical trial (currently or within the last 30 days)
8. Use of medications that may interfere with the effects of the study medications (any psychiatric medications).
9. fMRI related criteria including: metal implants (clips from operations, cochlea, large red/yellow tattoos in the neck area)
10. Tobacco smoking (\>10 cigarettes/day)
11. Consumption of alcoholic drinks (\>10/week)
25 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthias E Liechti, MD, MAS
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Basel, Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Basel
Basel, Canton of Basel-City, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BASEC 2016-01827
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.